Equities research analysts predict that Immune Design Corp. (NASDAQ:IMDZ) will announce earnings of ($0.65) per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Immune Design Corp.’s earnings, with the highest EPS estimate coming in at ($0.65) and the lowest estimate coming in at ($0.66). Immune Design Corp. posted earnings per share of ($0.71) during the same quarter last year, which would indicate a positive year over year growth rate of 8.5%. The business is expected to report its next quarterly earnings report on Tuesday, August 8th.

According to Zacks, analysts expect that Immune Design Corp. will report full year earnings of ($2.37) per share for the current fiscal year, with EPS estimates ranging from ($2.52) to ($2.17). For the next financial year, analysts expect that the company will report earnings of ($2.28) per share, with EPS estimates ranging from ($2.87) to ($1.44). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Immune Design Corp..

IMDZ has been the topic of several analyst reports. ValuEngine raised shares of Immune Design Corp. from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Cowen and Company reissued a “buy” rating on shares of Immune Design Corp. in a research report on Tuesday, June 6th. Jefferies Group LLC reissued a “buy” rating and issued a $18.00 target price on shares of Immune Design Corp. in a research report on Wednesday, June 28th. Finally, Zacks Investment Research upgraded shares of Immune Design Corp. from a “sell” rating to a “hold” rating in a research note on Thursday, May 18th.

Shares of Immune Design Corp. (IMDZ) opened at 9.15 on Thursday. The firm’s 50-day moving average price is $8.43 and its 200-day moving average price is $6.67. Immune Design Corp. has a 12 month low of $4.50 and a 12 month high of $11.10. The stock’s market capitalization is $233.97 million.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/20/zacks-brokerages-anticipate-immune-design-corp-imdz-will-post-earnings-of-0-65-per-share.html.

In related news, Director Lewis W. Coleman bought 8,000 shares of the company’s stock in a transaction on Friday, July 7th. The stock was bought at an average cost of $9.27 per share, with a total value of $74,160.00. Following the completion of the acquisition, the director now owns 40,000 shares in the company, valued at approximately $370,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Lewis W. Coleman bought 12,000 shares of the company’s stock in a transaction on Tuesday, July 11th. The stock was bought at an average cost of $9.05 per share, with a total value of $108,600.00. Following the completion of the acquisition, the director now owns 40,000 shares of the company’s stock, valued at approximately $362,000. The disclosure for this purchase can be found here. Insiders have purchased 30,000 shares of company stock valued at $272,760 over the last three months. 42.90% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of IMDZ. Bank of America Corp DE raised its stake in Immune Design Corp. by 123.3% in the first quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 8,418 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Immune Design Corp. by 170.0% in the first quarter. Renaissance Technologies LLC now owns 111,740 shares of the biotechnology company’s stock worth $760,000 after buying an additional 70,351 shares during the period. TIAA CREF Investment Management LLC raised its stake in shares of Immune Design Corp. by 18.9% in the first quarter. TIAA CREF Investment Management LLC now owns 45,574 shares of the biotechnology company’s stock worth $310,000 after buying an additional 7,236 shares during the period. FMR LLC raised its stake in shares of Immune Design Corp. by 0.4% in the first quarter. FMR LLC now owns 445,152 shares of the biotechnology company’s stock worth $3,027,000 after buying an additional 1,699 shares during the period. Finally, Victory Capital Management Inc. raised its stake in shares of Immune Design Corp. by 11.6% in the first quarter. Victory Capital Management Inc. now owns 1,937,554 shares of the biotechnology company’s stock worth $13,175,000 after buying an additional 202,149 shares during the period. 50.47% of the stock is owned by institutional investors.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Get a free copy of the Zacks research report on Immune Design Corp. (IMDZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immune Design Corp. (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.